Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2000-01-18
2008-09-02
Ton, Thaian N. (Department: 1632)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C435S375000, C435S006120
Reexamination Certificate
active
07419828
ABSTRACT:
The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention is specifically directed to methods of drug discovery using the activated gene products for compound testing.
REFERENCES:
patent: 4254226 (1981-03-01), Eisinger et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5641670 (1997-06-01), Treco et al.
patent: 5707830 (1998-01-01), Calos
patent: 5728551 (1998-03-01), Devine et al.
patent: 5733761 (1998-03-01), Treco et al.
patent: 5783385 (1998-07-01), Treco et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5830698 (1998-11-01), Reff et al.
patent: 5843772 (1998-12-01), Devine et al.
patent: 6135566 (2000-10-01), Anderson
patent: 6159705 (2000-12-01), Trueheart et al.
patent: 71893/94 (1994-06-01), None
patent: 0 779 362 (1990-12-01), None
patent: 0 742 285 (1996-11-01), None
patent: 2 707 091 (1995-01-01), None
patent: WO-92/20784 (1991-08-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 95/31560 (1995-11-01), None
patent: WO 96/04391 (1996-02-01), None
patent: WO 96/29411 (1996-09-01), None
patent: WO 98/12337 (1998-03-01), None
patent: WO 98/14614 (1998-04-01), None
patent: WO 99/07389 (1999-02-01), None
patent: WO 99/15650 (1999-04-01), None
patent: WO 99/50426 (1999-10-01), None
US 5,733,746, 03/1998, Treco et al. (withdrawn)
Caporale LH. Proc. Natl. Acad. Sci. USA. 92: 75-82, 1995.
Czerwinski et al. Proc. Natl. Acad. Sci. USA. 95:11520-11525, 1998.
Merriam-Webster's Collegiate Dictionary. “drug.” 1997. 10th Ed., p. 355.
Hay, Bruce A., et al., “P Element Insertion-Dependent Gene Activation In The Drosophila Eye,” Proc. Natl. Acad. Sci. USA, 94:5195-5200 (May 1997).
Xiong, J.-W., et al., “Large-Scale Screening for Developmental Genes in Embryonic Stem Cells and Embryoid Bodies Using Retroviral Entrapment Vectors,”Develop. Dynamics 212:181-197 (Jun. 1998).
Zhou, H., and Duesberg, P.H., “A retroviral promoter is sufficient to convert proto-srcto a transforming gene that is distinct from thesrcgene of Rous sarcoma virus,”Proc. Natl. Acad. Sci. USA 87:9128-9132 (1990).
Dialog File 351, Derwent WPI English Language abstract for FR 2 707 091, 6130/1993.
Barker, C.S., et al., “Activation of the Prolactin Receptor Gene by Promoter Insertion in a Moloney Murine Leukemia Virus-induced Rat Thymoma,”J. Virol. 66(11):6763-6768 (1992).
Black, A.C., et al., “HTLV-II Rex Binding and Activity Requires an Intact Splice Donor Site and a Specific RNA Secondary Structure,”AIDS Res.&Human Retroviruses 8:870 (1992).
Brikun, I., et al., “Analysis of CRP-CytR Interactions at theEscherichia coli udpPromoter,”J. Bacteriology 178(6):1614-1622 (Mar. 1996).
Buckler, A.J., et al., “Exon amplification: A strategy to isolate mammalian genes based on RNA splicing,”Proc. Natl. Acad. Sci. USA 88:4005-4009 (1991).
Butturini, A., et al., “Oncogenes in Human Leukemias,”Acta Haematologica 78(suppl. 1):2-10 (1987).
Butturini, A., and Gale, R.P., “Oncogenes and Human Leukemias,”Intl. J. Cell Cloning 6(1):2-24 (1988).
Chakraborty, A.K., et al., “Transforming function of proto-rasgenes depends on heterologous promoters and is enhanced by specific point mutations,”Proc. Natl. Acad. Sci. USA 88:2217-2221 (1991).
Chang, W., et al., “Enrichment of Insertional Mutants Following Retrovirus Gene Trap Selection,”Virol. 193:737-747 (1993).
Chow, W.-T., and Berg, D.E., “Tn5tacl, a derivative of transposon Tn5 that generates conditional mutations,”Proc. Natl. Acad. Sci. USA 85:6468-6472 (1988).
Church, D.M., et al., “Isolation of genes from complex sources of mammalian genomic DNA using exon amplification,”Nature Genetics 6:98-105 (1994).
Crabb, B.S., and Cowman, A.F., “Characterization of promoters and stable transfection by homologous and nonhomologous recombination inPlasmodium falciparum,” Proc. Natl. Acad. Sci. USA 93:7289-7294 (Jul. 1996).
Datson, W.A., et al., “Specific isolation of 3′-terminal exons of human genes by exon trapping,”Nucl. Acids Res. 22(20):4148-4153 (1994).
Datson, W.A., et al., “Scanning for genes in large genomic regions: cosmid-based exon trapping of multiple exons in a single product,”Nucl. Acids Res. 24:1105-1111 (Mar. 1996).
De Benedetti, A., and Rhoads, R.E., “A novel BK virus-based episomal vector for expression of foreign genes in mammalian cells,”Nucl. Acids Res. 19:1925-1931 (1991).
Dickson, C., et al., “Tumorigenesis by Mouse Mammary Tumor Virus: Proviral Activation of a Cellular Gene in the Common Integration Regionint-2,” Cell 37:529-536 (1984).
Dostatni, W., et al., “Use of Retroviral Vectors for Mapping of Splice Sites in Cottontail Rabbit Papillomavirus,”J. Gen. Virol. 69:3093-3100 (1988).
Duesberg, P.H., et al., “Cancer Genes by Non-Homologous Recombination,” in:Boundaries between Promotion and Progression during Carcinogenesis, Sudilovsky, O., et al., eds., Plenum Press, New York, NY, pp. 197-211 (1991).
Duyk, G.M., et al., “Exon trapping: A genetic screen to identify candidate transcribeed sequences in cloned mammalian genomic DNA,”Proc. Natl. Acad. Sci. USA 87:8995-8999 (1990).
Frankel, W., et al., “Retroviral Insertional mutagenesis of a target allele in a heterozygous murine cell line,”Proc. Natl. Acad. Sci. USA 82: 6600-6604 (1985).
Fujisawa, J.-I., et al., “Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor,”Proc. Natl. Acad. Sci. USA 82:2277-2281 (1985).
Fung, T,-K.T., et al., “Activation of the Cellular Oncogenec-erb8by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus,”Cell 33:357-368 (1983).
Goff, S.P., “Gene Isolation by Retroviral Tagging,”Meth. Enzymology 152:469-481 (1987).
Hayward, W.S., et al., “Activation of a cellularoncgene by promoter insertion in ALV-induced lymphoid leukosis,”Nature 290:475-480 (1981).
Jackson, I.J., “A reappraisal of non-consensus mRNA splice sites,”Nucl. Acids Res. 19(14):3795-3798 (1991).
Joshi, S., “A Putative Approach for Cloning -Silent' Genes Using Retroviral Vectors,”Med. Hypoth. 36:242-245 (1991).
Joyner, A.L., “Gene Targeting and Gene Trap Screens Using Embryonic Stem Cells: New Approaches to Mammalian Development,”BioEssays 13:649-656 (1991).
Junejo, F., et al., “Sequence analysis of the herpes simplex virus type 1 strain 17 variants 1704, 1705 and 1706 with respect to their origin and effect on the latency-associated transcript sequence,”J. Gen. Virol. 72:2311-2315 (1991).
King, W., et al., “Insertion Mutagenesis of Embryonal Carcinoma Cells by Retroviruses,”Science 228:554-558 (1985).
Kreissig, S., et al., “Expression of peptides encoded by exons in cloned mammalian DNA,”Nucl. Acids Res. 24:4358-4359 (Nov. 1996).
Lemay, G., and Jolicoeur, P., “Rearrangement of a DNA sequence homologous to a cell-virus junction fragment in several Moloneymurineleukemia virus-induced rat thymomas,”Proc. Natl. Acad. Sci. USA 81:38-42 (1984).
Liang, Y., et al., “Effects of Alternate RNA Splicing on Glucakinase Isoform Activi
ABT Holding Company
Singh Anoop K.
Thompson Hine LLP
Ton Thai-an N.
LandOfFree
Compositions and methods for non-targeted activation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for non-targeted activation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for non-targeted activation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969398